A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer

Inclusion Criteria: \- Documentation of Disease * Pathologically confirmed adenocarcinoma of the pancreas. * Presence of one of seven KRAS mutations: G12D, G12V, G12R, G12C, G12A, G12S, or G13D. * Definition of Disease * Patients must have resectable or borderline resectable localized disease as defined by NCCN Guidelines v2.2025. Staging CT or MRI of the chest/abdomen/pelvis at enrollment must be negative for metastatic disease. * Prior Treatment * Up to 4 doses of neoadjuvant mFOLFIRINOX are allowed prior to enrollment. Resolution of all toxicities of prior therapy or surgical procedures to baseline or Grade 1 (except for hypothyroidism requiring medication, which must have resolved to Grade ≤2), alopecia, and other toxicities considered clinically nonsignificant and/or stable on supportive therapy as determined by the investigator). * Age ≥18 years. * ECOG Performance Status 0-1 * Pregnancy and Nursing * Not pregnant or breastfeeding. * Evidence of post-menopausal status or a negative urinary or serum pregnancy test for females of child-bearing potential within 28 days prior to initiation of treatment. * Required Organ Function * Hematologic function: * ANC ≥1,500/mm³ * Platelets ≥100,000/mm³ * Hemoglobin ≥8.0 g/dL * Renal function: * Creatinine clearance ≥50 mL/min (Cockcroft-Gault formula or 24-hour urine collection). * Hepatic function: * Total bilirubin ≤1.5 × ULN (Gilbert's syndrome allowed up to ≤3 × ULN) * AST and ALT ≤3 × ULN Albumin: ≥2…